Safety and efficacy of durvalumab with R-CHOP or R2-CHOP in untreated, high-risk DLBCL: a phase 2, open-label trial

Patients with high-risk diffuse large B-cell lymphoma (DLBCL) have poor outcomes following first-line cyclophosphamide, doxorubicin, vincristine, prednisone, and rituximab (R-CHOP). Evidence shows chemotherapy and immune checkpoint blockade can increase antitumor efficacy. This study investigated du...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	International journal of hematology 2022-02, Vol.115 (2), p.222-232
Hauptverfasser:	Nowakowski, Grzegorz S., Willenbacher, Wolfgang, Greil, Richard, Larsen, Thomas S., Patel, Krish, Jäger, Ulrich, Manges, Robert F., Trümper, Lorenz, Everaus, Hele, Kalakonda, Nagesh, Brown, Peter, Jørgensen, Judit Meszaros, Cunningham, David, Dell’Aringa, Justine, Fox, Brian, Rubio, Neus Domper, Kilavuz, Nurgul, Casadebaig, Marie-Laure, Manzke, Oliver, Munoz, Javier
Format:	Artikel
Sprache:	eng
Schlagworte:	Anticancer properties Antitumor activity Apoptosis B-cell lymphoma Biomarkers Cancer therapies Chemotherapy Consolidation Cyclophosphamide Cytotoxicity Doxorubicin Gene expression Health risks Hematology Hospitals Immune checkpoint Immunotherapy Ligands Lymphocytes B Lymphoma Medical research Medicine Medicine & Public Health Monoclonal antibodies Oncology Original Article Prednisone Risk Rituximab Safety Targeted cancer therapy Vincristine
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!